Trial Profile
A multicenter, randomized, double-blind, placebo-controlled study to evaluate safety and efficacy of MEM 1003 [Memory Pharmaceuticals] in patients with mild to moderate Alzheimer's disease
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 18 Jan 2010
Price :
$35
*
At a glance
- Drugs MEM 1003 (Primary)
- Indications Alzheimer's disease
- Focus Therapeutic Use
- Sponsors Memory Pharmaceuticals
- 06 Mar 2008 Primary endpoint not reached, according to a Memory Pharmaceuticals media release.
- 16 Oct 2007 Top-line results reported
- 16 Oct 2007 Status change from in progress to completed.